Compare ATMU & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | LIVN |
|---|---|---|
| Founded | 1958 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.3B |
| IPO Year | 2023 | 2015 |
| Metric | ATMU | LIVN |
|---|---|---|
| Price | $43.21 | $76.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | $62.60 | ★ $90.55 |
| AVG Volume (30 Days) | ★ 587.7K | 567.1K |
| Earning Date | 11-06-2026 | 11-04-2026 |
| Dividend Yield | ★ 0.56% | N/A |
| EPS Growth | ★ 12.61 | N/A |
| EPS | 1.37 | ★ 2.33 |
| Revenue | ★ $1,764,300,000.00 | N/A |
| Revenue This Year | $14.05 | $9.65 |
| Revenue Next Year | $5.07 | $7.11 |
| P/E Ratio | ★ $31.11 | $32.58 |
| Revenue Growth | ★ 5.67 | N/A |
| 52 Week Low | $40.75 | $48.82 |
| 52 Week High | $66.50 | $85.76 |
| Indicator | ATMU | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 38.34 | 45.67 |
| Support Level | N/A | $74.69 |
| Resistance Level | $45.68 | $82.39 |
| Average True Range (ATR) | 1.33 | 2.07 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 37.54 | 36.02 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. It designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives approximately half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.